SPOTLIGHT: Pertuzumab slows breast cancer in study

Roche announced that a combination of Herceptin and pertuzumab slowed the spread of breast cancer. Pertuzumab is the first in a new class of agents known as HER dimerization inhibitors. HDIs block the ability of the HER2 receptor to collaborate with other HER receptor family members. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.